final action
on 29 Oct 2023
Last Applicant/ Owned by
Emil-von-Behring Str. 76
Marburg
DE
35041
Serial Number
97775859 filed on 01st Feb 2023
Registration Number
N/A
Correspondent Address
Scott D. Woldow
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bRead More
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies
No 97775859
No Service/Collective Mark
No 034845.366
Yes
Yes
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
29th Jan 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
29th Oct 2023 | NON-FINAL ACTION WRITTEN |
29th Oct 2023 | NON-FINAL ACTION E-MAILED |
29th Oct 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
27th Oct 2023 | ASSIGNED TO EXAMINER |
07th Feb 2023 | NEW APPLICATION ENTERED |
07th Feb 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |